AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,950,000 shares, a decline of 19.2% from the October 15th total of 4,890,000 shares. Based on an average daily trading volume, of 256,400 shares, the days-to-cover ratio is presently 15.4 days.

AlloVir Trading Up 2.9 %

Shares of AlloVir stock opened at $0.57 on Friday. The company has a market capitalization of $65.74 million, a PE ratio of -0.65 and a beta of 0.75. The stock’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $0.77. AlloVir has a 12 month low of $0.53 and a 12 month high of $2.49.

AlloVir (NASDAQ:ALVR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

Institutional Trading of AlloVir

A number of institutional investors have recently made changes to their positions in ALVR. Acadian Asset Management LLC raised its position in shares of AlloVir by 694.6% in the first quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,387,666 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of AlloVir by 127.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after purchasing an additional 54,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of AlloVir in the second quarter worth $55,000. Finally, Cubist Systematic Strategies LLC raised its stake in AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after purchasing an additional 30,072 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.